Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hepatitis B 1 infectiousdiseases
hepatitis C 5 infectiousdiseases
ribavirin 5 infectiousdiseasesdrugs
ritonavir 1 infectiousdiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
ribavirin 10246 hypertension. Interferon therapy, which was later modified to use pegylated interferon in combination with ribavirin , achieved SVR rates near 50% for difficult to treat genotype 1 patients. Because of the severe side
ribavirin 10382 50% for difficult to treat genotype 1 patients. Because of the severe side effects of interferon and ribavirin , older patients and patients with cirrhosis, impaired renal function, HIV/HBV coinfection, or other
ribavirin 10918 telaprevir and boceprevir had been approved earlier for use in combination with peg-interferon and ribavirin , the first interferon-free DAA therapy was not approved until 2014 with the introduction of daclatasvir
ribavirin 14122 post-SVR HCC is higher in patients treated with DAAs than in patients treated with interferon plus ribavirin , particularly among patients with advanced liver cirrhosis or a prior history of HCC [[30],[31],[34]].
ribavirin 15163 DAA-mediated HCV clearance have been proposed to explain any potential difference in HCC risk. IFN plus ribavirin therapy is associated with severe side effects due to its systemic effects and is typically administered
ritonavir 11732 DAA combination therapies include sofosbuvir plus ledipasvir (SOF/LDV), ombitasvir plus paritaprevir/ ritonavir (OMV/PTV/r), elbasvir plus grazoprevir (EBV/GPV), and glecaprevir plus pibrentasvir. With some variation
Select Disease Character Offset Disease Term Instance
hepatitis B 3013 Up to 850,000 new cases are diagnosed each year, and this number is expected to grow, especially in hepatitis B virus (HBV)-endemic regions, including sub-Saharan Africa and Southeast Asia that together account for
hepatitis C 886 (collection): 10/2018AbstractDespite the success of direct-acting antiviral (DAA) agents in treating chronic hepatitis C virus (HCV) infection, the number of cases of HCV-related hepatocellular carcinoma (HCC) is expected
hepatitis C 3752 to carcinogens such as aflatoxin B1, thorotrast, polyvinyl chloride, and carbon chloride. However, hepatitis C virus (HCV) infection is the leading cause of HCC in developed countries and is responsible for the
hepatitis C 45728 pathways alterations implicated in progression of this deadly and ascendant form of cancer.Figure 1The hepatitis C virus life cycle and targets of interferon and direct-acting antiviral therapies. (1) cell entry, (2)
hepatitis C 46716 hepatocellular carcinoma following post-sustained virological response in interferon-treated chronic hepatitis C patients (adapted from Baumert et al., 2017 [[49]]). Prospective studies are indicated using bold text.ReferenceCountryNFollow-Up
hepatitis C 48053 reporting incidence of hepatocellular carcinoma following post-sustained virological response in chronic hepatitis C patients treated using direct-acting antiviral therapy (adapted from Baumert et al., 2017 [[49]]). Prospective

You must be authorized to submit a review.